Attached files
file | filename |
---|---|
10-K - Predictive Oncology Inc. | v177566_10k.htm |
EX-32.1 - Predictive Oncology Inc. | v177566_ex32-1.htm |
EX-23.1 - Predictive Oncology Inc. | v177566_ex23-1.htm |
Exhibit
31.1
CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER
AND
PRINCIPAL FINANCIAL OFFICER
PURSUANT
TO SECTION 302 OF
THE
SARBANES-OXLEY ACT OF 2002
I, Kevin
R. Davidson, certify that:
1. I
have reviewed this Annual Report on Form 10-K for the year ending December 31,
2009 of BioDrain Medical, Inc.;
2. Based
on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
3. Based
on my knowledge, the financial statements and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and
for, the periods presented in this report;
4. Acting
as both the Principal Executive Officer and the Principal Financial Officer, I
am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant. This quarterly report does not include a report of
management’s assessment regarding internal control over financial reporting or
an attestation report of the Company’s registered public accounting firm due to
a transition period established by rules of the Securities and Exchange
Commission for newly public companies. I have;
(a)
Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under my supervision, to ensure that
material information relating to the small business issuer is made known to me
by others within this entity, particularly during the period in which this
report is being prepared;
(b)
Evaluated the effectiveness of the registrant's disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
(c)
Disclosed in this report any change in the small business issuer’s internal
control over financial reporting that occurred during the small business
issuer’s most recent fiscal quarter (the small business issuer’s fourth fiscal
quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the small business issuer’s internal
control over financial reporting;
5. I have
disclosed, based on our most recent evaluation of internal control over
financial reporting, to the small business issuer’s auditors and the audit
committee of small business issuer’s board of directors (or persons performing
the equivalent functions):
(a) All
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the small business issuer’s ability to record, process,
summarize and report financial information; and
(b) Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the small business issuer’s internal control over
financial reporting.
Date:
March 31, 2010
/s/ Kevin
R. Davidson
Kevin R.
Davidson
Chief
Executive Officer
(Principal
Executive Officer and Principal Financial Officer)